Immuneering Corp (IMRX) Hedge Fund Ownership (Q1 2026)

Immuneering Corp (IMRX)

91 + Investors. Track Smart Money conviction in IMRX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — IMRX

Based on 92 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q

For 4 consecutive quarters, more hedge funds added IMRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

92 hedge funds hold IMRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +171% more funds vs a year ago

fund count last 6Q

+58 new funds entered over the past year (+171% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks. The peak was reached in just 4 quarters from the low — a sharp move.

🟡

Slight buying edge — 56% buying

57 buying44 selling

Last quarter: 57 funds bought or added vs 44 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

➡️

Steady new buyers — ~27 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 12 → 34 → 32 → 27. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

📌

Mixed — 30% long-term, 55% new

■ 30% conviction (2yr+) ■ 14% medium ■ 55% new

Of the 92 current holders: 28 (30%) held >2 years, 13 held 1–2 years, and 51 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💎

Buying through price weakness — shares -16%, value -33%

Value

-33%

-15%

Last quarter: funds added -16% more shares while total portfolio value only changed -33%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📈

Growing discovery — still being found

4 → 12 → 34 → 32 → 27 new funds/Q

New funds entering each quarter: 12 → 34 → 32 → 27. A growing number of institutions are discovering IMRX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 42% veterans vs 48% newcomers

■ 42% veterans ■ 10% 1-2yr ■ 48% new

Entry-cohort mix of 98 holders: 41 (42%) are 2+ year veterans, 10 entered 1–2 years ago, and 47 (48%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 64% AUM from top-100 funds

64% from top-100 AUM funds

31 of 92 holders are among the 100 largest funds by AUM, controlling 64% of total institutional value in IMRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

6.2

out of 10

Moderate Exit Risk

Exit risk score 6.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	91	87	4.6%
13F Shares	27M	32M	-16.34%
Total Value	$132M	$199M	-33.69%
New Positions	26	32	-6
Increased Positions	29	27	+2
Closed Positions	22	14	+8
Reduced Positions	20	12	+8
Total Calls	3	4	-25.0%
Total Puts	3	3	-
PUT/CALL Ratio	1.0	0.75	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

4.6%

13F Shares

27M

32M

-16.34%

Total Value

$132M

$199M

-33.69%

New Positions

-6

Increased Positions

Closed Positions

Reduced Positions

Total Calls

-25.0%

Total Puts

PUT/CALL Ratio

1.0

0.75

Neutral

Institutional Holders (2026 Q2)

91 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in IMRX. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 IMRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Sanofi	2.53%	2,708,559	$13.5M
2	Alethea Capital Management, LLC	0.98%	472,935	$2.4M
3	DCF Advisers, LLC	0.70%	790,000	$3.9M
4	Occam Crest Management LP	0.59%	278,498	$1.1M
5	Pvg Asset Management Corp	0.42%	146,451	$731K
6	Levin Capital Strategies, L.P.	0.14%	414,000	$2.1M
7	Brandywine Managers, LLC	0.14%	55,066	$275K
8	Flower City Capital	0.12%	55,029	$275K
9	Permanent Capital Management, LP	0.10%	150,000	$748K
10	Kelsey Financial, LLC	0.06%	16,425	$82K
11	Burkehill Global Management, LP	0.05%	300,000	$1.5M
12	Wealth Effects LLC	0.05%	40,100	$200K
13	Future Financial Wealth Managment LLC	0.05%	18,000	$79K
14	Prosight Management, LP	0.03%	36,861	$184K
15	Summit Financial, LLC	0.02%	452,264	$2.3M
16	Thayer Partners, LLC / MA	0.02%	11,000	$55K
17	Palumbo Wealth Management LLC	0.02%	19,083	$95K
18	Berman McAleer LLC	0.01%	25,000	$125K
19	Tidemark, LLC	0.01%	10,000	$50K
20	Bridgeway Capital Management, LLC	0.01%	108,149	$540K
21	Connor, Clark & Lunn Investment Management Ltd.	0.01%	601,255	$3.0M
22	XTX Topco Ltd	0.00%	64,395	$321K
23	Nations Financial Group Inc, /Ia/ /Adv	0.00%	17,000	$85K
24	China Universal Asset Management Co., Ltd.	0.00%	12,797	$64K
25	State of Wyoming	0.00%	5,796	$29K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Immuneering Corp (IMRX)

What does the Smart Money Trend signal show for IMRX?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added IMRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for IMRX?

Slight buying edge — 56% buying: Last quarter: 57 funds bought or added vs 44 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for IMRX holders?

Elite ownership — 64% AUM from top-100 funds: 31 of 92 holders are among the 100 largest funds by AUM, controlling 64% of total institutional value in IMRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held IMRX?

Mixed — 30% long-term, 55% new: Of the 92 current holders: 28 (30%) held >2 years, 13 held 1–2 years, and 51 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Immuneering Corp (IMRX)

Smart Money Signals — IMRX

Buying streak — 4 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +171% more funds vs a year ago

Slight buying edge — 56% buying

Steady new buyers — ~27 new funds per quarter

Mixed — 30% long-term, 55% new

Buying through price weakness — shares -16%, value -33%

Growing discovery — still being found

Veteran-anchored — 42% veterans vs 48% newcomers

Elite ownership — 64% AUM from top-100 funds

Institutional Sentiment Summary — IMRX

Hedge Fund Ownership: IMRX

Market Analysis: IMRX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: IMRX

Hedge Fund Positioning: IMRX

Statistics: IMRX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Immuneering Corp (IMRX)

Welcome to 13Foresight!